Advancing Antibody-Based Therapies

We are Patient Centric

We are Science-Based

We are Performance Driven

31st Annual Piper Jaffray Healthcare Conference

The company will participate in a fireside chat on Tuesday, December 3, 2019 at 11:00 a.m. Eastern Time in New York, NY.
To access the audio webcast, click here
 


Jefferies 2019 London Healthcare Conference

The company presented on Wednesday, November 20, 2019 at 4:40 p.m. Greenwich Mean Time in London, UK. To access a recording of audio webcast, click here
 


Immunomedics Third Quarter 2019 Earnings Call

The Company hosted a conference call and live audio webcast on October 30, 2019, at 5:00 pm Eastern Time. To access a recording of this conference call, click here


2019 Cantor Global Healthcare Conference

The company presented on Friday, October 4, 2019 at 10:05 a.m. Eastern Time in New York, N.Y. To access recording of the audio webcast, click here


Immunomedics Investor Event During ESMO Congress 2019

The Company hosted an Investor Event on Saturday, September 28, 2019 at 6:30 p.m. Central European Summer Time (12:30 p.m. ET) in Barcelona, Spain, during the ESMO Congress 2019. To access recording of the webcast, click here


Morgan Stanley 17th Annual Global Healthcare Conference

The Company participated in a fireside chat on Monday, September 9, 2019 at 11:40 a.m. Eastern Time. To access recording of audio webcast, click here


2019 Wells Fargo Securities Healthcare Conference

The Company participated in a fireside chat on Wednesday, September 4, 2019 at 1:15 p.m. Eastern Time. To access recording of audio webcast, click here


Immunomedics Second Quarter 2019 Earnings Call

The Company hosted a conference call and live audio webcast on August 7, 2019, at 5:00 pm Eastern Time. To access a recording of this conference call, click here


Our Drive to Improve Targeted Therapies of Diseases

We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.

Our Science

Pipeline

We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.

Learn More

Explore how we turn our research into reality.

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Clinical Trials